In vivo models are essential for preclinical drug development. Medicilon provides diverse pharmacodynamic and pharmacologic models for oncology, metabolic, neurological, cardiovascular, inflammatory, digestive, and ocular diseases.
Our comprehensive tumor and non-tumor models ensure precise efficacy evaluation, accelerating the path from discovery to clinical application.
At Medicilon, our integrated ADME/DMPK, pharmacodynamics (PD), and safety assessment studies provide high-quality, regulatory-compliant data, ensuring drug candidates advance efficiently from early research to clinical trials.
Oncology, neurology, cardiovascular, metabolic, etc.
500+ models with established methodologies
Translating discovery into clinical application
Medicilon provides GLP and non-GLP safety assessments tailored to your drug development needs. Whether for early research or regulatory submission, our precise solutions support every stage of your project.
Medicilon offers a comprehensive range of tumor and non-tumor models to evaluate drug efficacy and safety. With 186+ xenograft and 100+ PDX models, plus extensive CNS, cardiovascular, and metabolic disease models, we provide precise insights to accelerate breakthrough therapies.
Conjunctival tissue proliferation and NV
Diabetic retinopathy (DR)
Choroidal neovascularization (CNV) and subretinal fibrosis
Corneal neovascularization (Corneal NV)
Acute ocular inflammation models
Dry Eye